Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 170

1.

Integrative analysis of genome-wide loss of heterozygosity and monoallelic expression at nucleotide resolution reveals disrupted pathways in triple-negative breast cancer.

Ha G, Roth A, Lai D, Bashashati A, Ding J, Goya R, Giuliany R, Rosner J, Oloumi A, Shumansky K, Chin SF, Turashvili G, Hirst M, Caldas C, Marra MA, Aparicio S, Shah SP.

Genome Res. 2012 Oct;22(10):1995-2007. doi: 10.1101/gr.137570.112. Epub 2012 May 25.

2.

Landscape of somatic allelic imbalances and copy number alterations in HER2-amplified breast cancer.

Staaf J, Jönsson G, Ringnér M, Baldetorp B, Borg A.

Breast Cancer Res. 2011;13(6):R129. doi: 10.1186/bcr3075. Epub 2011 Dec 14.

3.

Integration of transcript expression, copy number and LOH analysis of infiltrating ductal carcinoma of the breast.

Hawthorn L, Luce J, Stein L, Rothschild J.

BMC Cancer. 2010 Aug 27;10:460. doi: 10.1186/1471-2407-10-460.

4.

Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities.

Craig DW, O'Shaughnessy JA, Kiefer JA, Aldrich J, Sinari S, Moses TM, Wong S, Dinh J, Christoforides A, Blum JL, Aitelli CL, Osborne CR, Izatt T, Kurdoglu A, Baker A, Koeman J, Barbacioru C, Sakarya O, De La Vega FM, Siddiqui A, Hoang L, Billings PR, Salhia B, Tolcher AW, Trent JM, Mousses S, Von Hoff D, Carpten JD.

Mol Cancer Ther. 2013 Jan;12(1):104-16. doi: 10.1158/1535-7163.MCT-12-0781. Epub 2012 Nov 19.

5.

Allele-specific loss of heterozygosity at the DAL-1/4.1B (EPB41L3) tumor-suppressor gene locus in the absence of mutation.

Kittiniyom K, Mastronardi M, Roemer M, Wells WA, Greenberg ER, Titus-Ernstoff L, Newsham IF.

Genes Chromosomes Cancer. 2004 Jul;40(3):190-203.

PMID:
15138999
6.

A new method to detect loss of heterozygosity using cohort heterozygosity comparisons.

Green MR, Jardine P, Wood P, Wellwood J, Lea RA, Marlton P, Griffiths LR.

BMC Cancer. 2010 May 12;10:195. doi: 10.1186/1471-2407-10-195.

7.

Combined array-comparative genomic hybridization and single-nucleotide polymorphism-loss of heterozygosity analysis reveals complex genetic alterations in cervical cancer.

Kloth JN, Oosting J, van Wezel T, Szuhai K, Knijnenburg J, Gorter A, Kenter GG, Fleuren GJ, Jordanova ES.

BMC Genomics. 2007 Feb 20;8:53.

8.

Genomewide scan for loss of heterozygosity and chromosomal amplification in breast carcinoma using single-nucleotide polymorphism arrays.

Argos M, Kibriya MG, Jasmine F, Olopade OI, Su T, Hibshoosh H, Ahsan H.

Cancer Genet Cytogenet. 2008 Apr 15;182(2):69-74. doi: 10.1016/j.cancergencyto.2008.01.001.

9.

ATBF1 and NQO1 as candidate targets for allelic loss at chromosome arm 16q in breast cancer: absence of somatic ATBF1 mutations and no role for the C609T NQO1 polymorphism.

Cleton-Jansen AM, van Eijk R, Lombaerts M, Schmidt MK, Van't Veer LJ, Philippo K, Zimmerman RM, Peterse JL, Smit VT, van Wezel T, Cornelisse CJ.

BMC Cancer. 2008 Apr 16;8:105. doi: 10.1186/1471-2407-8-105.

10.

Widespread Non-Canonical Epigenetic Modifications in MMTV-NeuT Breast Cancer.

Felts SJ, Van Keulen VP, Hansen MJ, Bell MP, Allen K, Belachew AA, Vile RG, Cunningham JM, Hoskin TL, Pankratz VS, Pease LR.

Neoplasia. 2015 Apr;17(4):348-57. doi: 10.1016/j.neo.2015.02.006.

11.
12.

Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.

Timms KM, Abkevich V, Hughes E, Neff C, Reid J, Morris B, Kalva S, Potter J, Tran TV, Chen J, Iliev D, Sangale Z, Tikishvili E, Perry M, Zharkikh A, Gutin A, Lanchbury JS.

Breast Cancer Res. 2014 Dec 5;16(6):475. doi: 10.1186/s13058-014-0475-x.

13.

Copy number neutral loss of heterozygosity at 17p and homozygous mutations of TP53 are associated with complex chromosomal aberrations in patients newly diagnosed with myelodysplastic syndromes.

Svobodova K, Zemanova Z, Lhotska H, Novakova M, Podskalska L, Belickova M, Brezinova J, Sarova I, Izakova S, Lizcova L, Berkova A, Siskova M, Jonasova A, Cermak J, Michalova K.

Leuk Res. 2016 Mar;42:7-12. doi: 10.1016/j.leukres.2016.01.009. Epub 2016 Jan 24.

PMID:
26851439
14.

Altered expression and loss of heterozygosity of the LOT1 gene in ovarian cancer.

Cvetkovic D, Pisarcik D, Lee C, Hamilton TC, Abdollahi A.

Gynecol Oncol. 2004 Dec;95(3):449-55.

PMID:
15581945
15.

Tumor transcriptome sequencing reveals allelic expression imbalances associated with copy number alterations.

Tuch BB, Laborde RR, Xu X, Gu J, Chung CB, Monighetti CK, Stanley SJ, Olsen KD, Kasperbauer JL, Moore EJ, Broomer AJ, Tan R, Brzoska PM, Muller MW, Siddiqui AS, Asmann YW, Sun Y, Kuersten S, Barker MA, De La Vega FM, Smith DI.

PLoS One. 2010 Feb 19;5(2):e9317. doi: 10.1371/journal.pone.0009317.

16.

Are there any more ovarian tumor suppressor genes? A new perspective using ultra high-resolution copy number and loss of heterozygosity analysis.

Gorringe KL, Ramakrishna M, Williams LH, Sridhar A, Boyle SE, Bearfoot JL, Li J, Anglesio MS, Campbell IG.

Genes Chromosomes Cancer. 2009 Oct;48(10):931-42. doi: 10.1002/gcc.20694.

PMID:
19603523
17.

Novel insights into breast cancer genetic variance through RNA sequencing.

Horvath A, Pakala SB, Mudvari P, Reddy SD, Ohshiro K, Casimiro S, Pires R, Fuqua SA, Toi M, Costa L, Nair SS, Sukumar S, Kumar R.

Sci Rep. 2013;3:2256. doi: 10.1038/srep02256.

19.

Genome-wide analysis of neuroblastomas using high-density single nucleotide polymorphism arrays.

George RE, Attiyeh EF, Li S, Moreau LA, Neuberg D, Li C, Fox EA, Meyerson M, Diller L, Fortina P, Look AT, Maris JM.

PLoS One. 2007 Feb 28;2(2):e255.

Supplemental Content

Support Center